Articles with keyword biomarkers

• Biomarkers for early diagnostics of brain tumors

  I.A. Medyanik, A.S. Gordetsov, K.S. Yashin, O.V. Krasnikova, A.P. Frayerman, Z.О. Shenkarev, N.N. Karyakin

  biomarkers of glioma, microRNK, infrared spectroscopy, early diagnostics, brain tumors.

• Biomarkers predicting the effect of immunotherapy: what you need to know in practice?

  A.M. Konstantinova

  immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.

• CRITICAL VIEW OF EFFICACY ANTIANGIOGENIC THERAPY IN ONCOLOGY

  M.Yu. Fedyanin, A.A. Tryakin, I.A. Pokataev

  antiangiogenic therapy, bevacizumab, resistance, biomarkers.

• IMMUNOTHERAPY

  N.M. Volkov

  cancer immunotherapy, effectiveness, toxicity, hyperprogression, predictive biomarkers.

• Morphological methods of malignant tumors investigation

  K.V. Shelekhova,A.S. Konstantinov

  morphology, methods, prognostic and predictive biomarkers, immunohistochemistry, FISH, ISH.

• Organizational, technological and scientific issues of morphology and molecular genetics

  K.V. Shelekhova, V.A. Kheinshtein

  morphology, cold ischemia, formalin fixation, delay, prognostic and predictive biomarkers, immunohistochemistry, FISH, ISH.

• Early cancer detection: current status and emerging strategies

  Francisco Gutierrez-Delgado

  early cancer detection, cancer screening, breast cancer, mammography, breast thermography, cancer imaging, cancer biomarkers, lung cancer

• Efficacy of immune checkpoints inhibitors in the treatment of solid tumors

  A.A. Rumyantsev, S.A. Tjulandin

  drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy

• EVOLUTION OF SCREENING FOR PROSTATE CANCER

  A.I. Novikov

  prostate cancer, screening, prostate-specific antigen (PSA), prostate health index, multiparameter magnetic-resonance tomography (mpMRI), biomarkers (Select MDX, HOXX6, DLX1), genetic mutations (BRCA1/2, HOXB13).